Subscribe to Updates

    Get the latest news from Legacy Medi4!

    Our Picks

    Sean Dyche: Everton confirm former Burnley boss as their new manager on two-and-a-half-year contract | Football News

    January 30, 2023

    Actress Annie Wersching known for TV shows 24, The Last of Us passes away at 45

    January 30, 2023

    Salesforce could grow earnings at 20% or more due to activist, layoffs (CRM)

    January 30, 2023

    UK cost-of-living crisis pushes mothers to the brink | Poverty and Development

    January 30, 2023
    Facebook Twitter Instagram
    • Privacy Policy
    • Contact Us
    • About Us
    • Disclaimer
    Facebook Twitter Instagram YouTube
    Legacy Medi4Legacy Medi4
    • World News
    • Business
    • Entertainment
    • Health
    • Science
    • Sports
    • Technology
    Legacy Medi4Legacy Medi4
    Home»Business»Novo, Lilly to benefit the most from obesity, but Cowen says don’t ignore other players
    Business

    Novo, Lilly to benefit the most from obesity, but Cowen says don’t ignore other players

    Todd LivingstonBy Todd LivingstonNovember 19, 2022No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    An Asian man measured his fat belly with a measuring tape in public

    Deepak Verma

    Global drug sales are expected to hit ~$30B by 2020, according to Cowen, with Novo Nordisk ( NVO ) and Eli Lilly (NYSE: LLY) capable of controlling the market.

    But the Wall Street firm also tells investors not to just look at other pharmas with weight loss products in the pipeline, but look for companies that are developing medical devices and digital therapies to pave the way in the obesity treatment space.

    In the report of Nov. 18, Cowen said that treatment of obesity is in its new form. Only 30% of obese people are diagnosed and treatment is very limited. The company added that medical treatment is only used by 1%-2% of obese patients.

    In a June survey, Cowen found that obesity specialists reported seeing medication as appropriate for ~60% of their patients. This compares to 20% for surgery. A survey of doctors and payers conducted in October by Cowen found that they agree that the number of patients without diabetes who take weight loss drugs has increased significantly.

    Pharmacotherapy

    Novo Nordisk (NVO) and Lilly (LLY) want to expand the use of obesity drugs, and quickly, with the GLP-1 receptor agonists, Wegovy (semaglutide) and tirzepatide. Cowen projects Wegovy sales of over $7B and over tirzepatide sales of more than $11B in 2030. Tirzepatide is currently approved as a type 2 diabetes therapy under the name Mounjaro but Lilly (LLY) is pursuing the drug for weight loss in the third phase.

    Cowen is also bullish on Novo’s ( NVO ) CagriSema, a combination of semaglutide and a novel amylin analogue, cagrilintide. Pharma released positive phase 2 results in August showing reductions in blood sugar and weight gain. Phase 3 should begin in 2023. Cowen sees $5B in CagriSema sales if data continues to improve.

    In the pipeline, Lilly (LLY) has the GLP-1R/GIPR/GCGR triple agonist retatrutide in phase 2 with a data update expected in January 2023. Other big pharmas with mid- to late-stage obesity candidates include Merck’s (NYSE: MRKGLP-1R/GCGR dual agonist efinopegdutide (data update in January), Pfizer’s (NYSE: PFE) oral treatment danuglipron, AltImmune’s (ALT) GLP-1R/GCGR dual agonist pemvidutide (ALT-801 (data update June 2023), and AstraZeneca’s (AZN) GLP-1/GCGR dual agonist cotadutide (update July 2025).

    Medical Devices

    In this area, Cowen sees Apollo Endoscopy (APEN) as its main option for obesity. The company’s endoscopic sleeve gastroplasty (ESG) system uses its OverStitch endoscopic suturing system. The company is developing the OverStitch NXT single channel endoscopic suturing system which is said to have performance-enhancing features to make it easier to use, expanding the scope of the technology.

    Cowen also showed off Apollo’s ( APEN ) space-based device, the Orbera Intragastric Balloon System, calling it “the world’s leading intragastric balloon.” The company added that the device can cause 10% weight loss.

    Cowen presented ReShape Lifesciences (RSLS) which manufactures Obalon, an intragastric balloon that contains air. In one study, Obalon caused an average of 4.2% weight loss over 12 weeks, making it significantly lower than other balloons.

    Digital Therapeutics

    Although Better Therapeutics ( BTTX ) is developing BT-001 as a digital therapy (“PDT”) for type 2 diabetes, Cowen said the product from the program could be used in obesity. PDT, which is often found in a program, uses emotional intelligence to identify unhealthy lifestyle habits and food choices and make suggestions for change.

    Source link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Todd Livingston

    Related Posts

    Salesforce could grow earnings at 20% or more due to activist, layoffs (CRM)

    January 30, 2023

    Morgan Stanley’s Kayello to step down as MENA head By Reuters

    January 30, 2023

    Euronav makes second arbitration request in nixed merger deal with Frontline (NYSE:FRO)

    January 30, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Sean Dyche: Everton confirm former Burnley boss as their new manager on two-and-a-half-year contract | Football News

    January 30, 2023

    Actress Annie Wersching known for TV shows 24, The Last of Us passes away at 45

    January 30, 2023

    Salesforce could grow earnings at 20% or more due to activist, layoffs (CRM)

    January 30, 2023

    UK cost-of-living crisis pushes mothers to the brink | Poverty and Development

    January 30, 2023

    Subscribe to Updates

    Get the latest news from Legacy Medi4!

    Our Picks

    Sean Dyche: Everton confirm former Burnley boss as their new manager on two-and-a-half-year contract | Football News

    January 30, 2023

    Actress Annie Wersching known for TV shows 24, The Last of Us passes away at 45

    January 30, 2023

    Salesforce could grow earnings at 20% or more due to activist, layoffs (CRM)

    January 30, 2023

    Type above and press Enter to search. Press Esc to cancel.